Lifeward Ltd. announced on September 8, 2025, that it has received CE mark approval for the ReWalk 7 Personal Exoskeleton, clearing it for commercial sale in Europe. This regulatory milestone allows the newest generation of the ReWalk device to be available to European customers.
The ReWalk 7 features innovative enhancements such as cloud connectivity, push-button control, customizable walking speeds, and seamless activation of stairs and curbs. These improvements are designed to deliver superior control and real-world mobility for individuals with spinal cord injury (SCI).
European customers currently account for approximately 40% of Lifeward’s exoskeleton sales, with the majority generated through Lifeward GmbH in Germany. Reimbursement for personal exoskeletons is broadly established in Germany, positioning the company for meaningful near-term commercial adoption and revenue growth in the region.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.